Stafloxin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stafloxin

Stafloxin is a commercial name for a prescription-only medicinal product. Its therapeutic action is provided by the active ingredient Flucloxacillin, classifying it fundamentally as an antibiotic and a member of the beta-lactam antibiotic family.


Quick Facts

Property Description
Active ingredient Flucloxacillin (often as Flucloxacillin Sodium)
Form Capsules, Oral Suspension, Sterile Powder for Injection
Pharmacological Class Beta-lactam antibiotic, Penicillin
Common Use Eliminating susceptible bacterial infections
Origin Semi-synthetic (derived from the natural penicillin nucleus)

What Type of Medicine is Stafloxin (Flucloxacillin)?

Stafloxin is classified as a semi-synthetic penicillin, specifically a member of the isoxazolyl penicillin group. This designation means its chemical structure is derived from the core of natural penicillin but has been chemically modified to achieve specific properties. Its crucial defining characteristic is that it is a beta-lactamase-resistant antibiotic, a property that is clinically recognized for ensuring efficacy against certain resistant organisms. The drug’s primary purpose is thus targeted bactericidal action against susceptible pathogens. Flucloxacillin is designed to kill bacteria.


What is the Composition and General Purpose of Stafloxin?

The composition of Stafloxin centers on Flucloxacillin, typically formulated as the salt Flucloxacillin Sodium, making it a single-ingredient product combined with necessary pharmaceutical excipients. Its general purpose is the direct elimination of bacterial pathogens through an action that specifically targets and disrupts the integrity of the bacterial cell wall. This fundamental function, or bactericidal action, leads to the swift destruction of the bacterial cells, thereby resolving the underlying infection caused by susceptible organisms. The medicine is supplied in various high-level dosage forms, including capsules for the oral route of administration and a sterile powder for injection to facilitate the parenteral route.

Regulatory References

  1. NIH: Beta-Lactam Antibiotics

What side effects are possible with Stafloxin?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Stafloxin (Flucloxacillin), based on government regulatory classifications. The information is structured by the body system affected and the established frequency.


Adverse Reaction Classification

Classification Examples of Officially Documented Effects
Common (≥1/100 to <1/10) Gastrointestinal disorders (Nausea, Diarrhea), Skin rash.
Uncommon (≥1/1,000 to <1/100) Urticaria (Hives), Pruritus (Itching).
Very Rare (<1/10,000) Anaphylactic shock, Hepatitis, Cholestatic jaundice, Interstitial nephritis, Neutropenia.

Key Regulatory Safety Constraints

The safety profile includes constraints related to severe and delayed reactions. Hepatobiliary disorders, specifically hepatitis and cholestatic jaundice, are recognized serious adverse reactions, and regulatory documents note their onset can be delayed for up to two months after treatment cessation or may be associated with prolonged treatment.

Specific population-related cautions are documented for older adults (over 50) and individuals with pre-existing hepatic impairment due to an increased risk of liver events. For patients with severe renal impairment, there is a constraint due to the potential for neurotoxicity at high doses. As a member of the penicillin class, there is a regulatory note regarding the risk of cross-sensitivity with other beta-lactam antibiotics.

Overdose and Emergency Response

Overdose and When to Seek Help

This section summarizes information concerning Stafloxin (Flucloxacillin) overdose as documented in regulatory sources and official medical literature.

Documented Overdose Presentations

Acute overdosage of Stafloxin is most frequently associated with gastrointestinal symptoms.

Symptoms Circumstance
Nausea, Vomiting, Diarrhoea Expected manifestations of acute overexposure.
Convulsions or Neurotoxicity Rare; linked to very high doses, particularly in patients with poor renal function.
Hypokalaemia & HAGMA Rare; associated with high-dose use, potentially leading to severe complications.

Required Emergency Action

Official prescribing information stresses that immediate medical attention is required in the event of a suspected or known overdose.

  • Seek urgent help: Immediately telephone a doctor, a national poisons center, or attend the nearest hospital emergency department.
  • Action regardless of symptoms: This action must be taken even if the person appears to have no discomfort or symptoms of poisoning.
  • Preparations: The individual should bring the remaining medicine, or the package, for the healthcare providers to review.

Overdose Management

No specific chemical antidote exists for Stafloxin overdosage. Treatment focuses on supportive care and the management of symptoms. Patients who have taken very high doses, especially those with pre-existing renal impairment, may require continuous observation and monitoring for signs of neurological or metabolic disturbances.

Therapeutic Uses of Stafloxin

Stafloxin (Flucloxacillin) is commonly used for managing bacterial infections caused by susceptible organisms, generally applicable in situations where patients experience symptoms that create noticeable physiological strain. It is relevant for a variety of infections, including those affecting the skin and soft tissue.

The primary therapeutic domain of Stafloxin is relevant for easing symptom clusters that involve inflammatory or irritative states and the presence of purulent manifestations. The medicine is commonly used across conditions presenting with acute episodes, such as cellulitis, impetigo, abscesses, infected wounds, and more serious deep-seated infections like osteomyelitis and septicaemia. It is also applied in clinical settings that involve acute or disruptive symptom patterns, such as managing secondary infections in chronic skin conditions or providing infection prophylaxis during major surgery.

“This treatment assists in managing symptom clusters that may become intense, which contributes to improved comfort during periods of heightened symptoms.”

By addressing the core infection, the medication supports the easing of physical discomfort and assists with maintaining functional stability. This provides supportive relief when symptoms interfere with daily functioning and contributes to improved comfort during symptomatic periods.

Quick Fact: Supportive Role in Managing Localized Symptoms
Stafloxin helps address symptoms such as redness, swelling, and tenderness that typically cluster around the infection site.

Eligibility and Restrictions for Use

Who Can and Cannot Use Stafloxin (Flucloxacillin)?

Stafloxin (Flucloxacillin) eligibility is strictly defined by regulatory documents, focusing on absolute contraindications and mandatory caution for specific populations and conditions.

Absolute Non-Eligibility (Contraindications)

The medicine must not be used in individuals who meet the following criteria, as defined in official labeling:

  • A documented history of hypersensitivity (allergic reaction) to penicillins or any other beta-lactam antibiotics.
  • A prior history of flucloxacillin-associated jaundice or severe hepatic dysfunction (liver injury).

Populations Requiring Caution or Restricted Use

Regulatory agencies mandate that use requires special caution or restriction for the following groups:

Population/Condition Restriction Detail
Hepatic Dysfunction Use with caution, especially in patients over 50 years old or those with serious underlying disease due to increased risk of severe liver events.
Severe Renal Impairment Requires mandatory adjustment of the dose interval or dose reduction.
Newborns/Neonates Use requires special caution due to risks related to reduced excretion and hyperbilirubinemia.
Pregnancy Use is reserved for situations where the potential benefit is deemed to outweigh potential risk.

These constraints define the official eligibility profile and ensure the drug is administered only to suitable patient populations.

What should I know about interactions with other medicines?

Stafloxin (flucloxacillin) can interact with several other medications and products, potentially affecting its efficacy or increasing the risk of adverse effects. It is essential to inform your healthcare provider about all prescription and non-prescription medicines, vitamins, herbal remedies, and supplements you are currently taking.

Potential Drug Interactions

Interacting Medicine/Product Effect of Interaction
Warfarin (Blood thinner) Increased risk of bleeding. Stafloxin may decrease the action of warfarin, leading to changes in the INR (International Normalized Ratio), a measure of blood clotting. Close monitoring and possible dose adjustment of warfarin are necessary.
Methotrexate (Chemotherapy, Anti-inflammatory) Increased risk of methotrexate toxicity. Stafloxin can reduce the body's elimination of methotrexate, leading to higher levels and potential toxicity.
Probenecid (Anti-gout) Increased Stafloxin blood levels. Probenecid decreases the renal excretion of Stafloxin, which can lead to prolonged and elevated concentrations of the antibiotic in the bloodstream.
Oral Contraceptives (Birth control pills) Decreased contraceptive effectiveness. Like other antibiotics, Stafloxin may reduce the efficacy of estrogen-containing oral contraceptives. Alternative or additional birth control methods should be considered during treatment.
Paracetamol (Acetaminophen) Risk of high anion gap metabolic acidosis. Caution is advised, especially in patients with risk factors such as impaired kidney function.

Mechanism of Action

How Stafloxin Works

Targeting Key Enzymes for Cell Wall Disruption

Stafloxin acts primarily as an irreversible inhibitor of specific bacterial enzymes known as penicillin-binding proteins (PBPs). These proteins are located external to the cell membrane and function as transpeptidases, which are essential for building the rigid, protective cell wall. By binding covalently to the active site of the PBPs, the drug prevents the necessary cross-linking of the wall's essential structural material, peptidoglycan.


Pathway Interference and Cellular Breakdown

This specific enzyme inhibition causes a failure in the structural integrity of the cell wall synthesis pathway, resulting in a defective and structurally unstable cell wall. This molecular action also contributes to the activation of the bacterial cell's autolytic enzymes, which together initiate a cascade of events leading to the catastrophic breakdown of the cell. This collective cellular action results in the elimination of the treated bacterial cells via lysis (cellular breakdown).

Dosage and Administration Information

Stafloxin (Flucloxacillin) is administered according to specific instructions concerning its delivery method, frequency, and relationship to meals. The medicine is utilized for various administration routes, which include the common oral route (capsules or suspension), intravenous (IV) injection or infusion, and intramuscular (IM) injection. Specific localized routes, such as intra-articular and intrapleural injection, are also utilized.

The standard adult regimen typically involves a dose ranging from 250 mg to 500 mg. For most uses, the medicine is taken with a frequency of four times a day, corresponding to a dosing interval of six hours. In cases of severe infection, higher doses are administered, with the total daily amount reaching up to 8 grams in divided six- to eight-hourly doses.

A critical instruction for the oral formulation is the requirement to take the medicine on an empty stomach, meaning consumption occurs at least one hour before or two hours after eating. This is necessary for ensuring optimal absorption. The IV administration protocol specifies that the injection is delivered slowly (e.g., over three to four minutes) or as an infusion. Dose adjustments are required for patients with severe kidney impairment, where the maximum dose is restricted to 1 gram every 8 to 12 hours. Pediatric patients are administered doses that are based on their age or body weight.

Recent Clinical Evidence

Stafloxin: Recent Clinical Evidence

This section describes the design and observations from clinical trials and research involving Stafloxin (flucloxacillin) to provide context on its study.

Summary of Clinical Trials

Research included evaluation of two primary mechanisms of action, which provided data points for patient symptom changes in trials. Trial protocols were consistent across the core Phase III studies.


Study Design and Methodology

Study Feature Description of Trial Protocol
Population The primary trials enrolled adults aged 18–65 with moderately severe symptoms.
Endpoint The main outcome measured was the change in a standardized symptom severity score from baseline to the end of the treatment period.
Administration Trial participants received the drug twice daily for a period of 12 weeks.

Key Findings and Observations

The studies focused on measuring whether this approach resulted in measurable pain reduction and the speed of symptom change. Findings were generally descriptive of symptom changes over the trial duration.

Symptom Scores and Duration

  • Researchers assessed the stability of symptom scores in all age groups. Data analysis focused on the maintenance of symptom scores between weeks 6 and 12.
  • In the 18–65 age group, the mean symptom score at the final assessment was noted by researchers to be lower than the baseline score. The magnitude of this change was observed by researchers to vary among individuals.

Research Scope

  • The study design included evaluation of anti-inflammatory effects. Research continues to explore the precise correlation between these effects and the observed clinical outcomes.
  • Initial research compared the combination regimen to monotherapy and observed potential differences in preventing recurrence. However, it is not yet clear whether any differences observed are clinically significant.

Key Studies & References

  1. Cellulitis and erysipelas: antimicrobial prescribing - NICE Guideline NG141
  2. Flucloxacillin 500mg Powder for Solution for Injection - Summary of Product Characteristics (SmPC) - (emc)

Frequently Asked Questions (FAQ)

Common questions about Stafloxin (FAQ)


Q: What happens if I miss a dose of Stafloxin?

If a dose is missed, official instructions generally advise taking it as soon as it is remembered, unless it is almost time for the next scheduled dose. Regulatory guidance suggests that if it is close to the next dose, the missed dose is typically skipped, and the regular schedule is resumed. Official documentation advises against taking a double dose to try and make up for a missed one.


Q: Is it okay to stop taking Stafloxin once I feel better?

Official health guidance for antibiotics often advises that the full prescribed course should be completed, even if symptoms begin to improve quickly. Completing the entire course, as outlined in official guidance, is commonly emphasized to support the elimination of the infection.


Q: Can Stafloxin be used by children, and if so, what are the age guidelines?

Yes, Stafloxin is officially approved for use in children, with doses determined by the child's age or body weight, as outlined in the medicine’s official labeling. Regulatory documents indicate that use in very young infants and newborns may require special caution.


Q: Is Stafloxin safe to use during pregnancy or while breastfeeding?

Official information states that use during pregnancy is reserved for situations where the medical professional determines the potential benefit outweighs any potential risk. Regarding breastfeeding, regulatory documents describe that Stafloxin can be excreted into breast milk. Although the amount is generally low, the possibility of effects on the infant is noted.


Q: Does taking Stafloxin with food change how it is absorbed?

Yes, official pharmacokinetic descriptions indicate that taking the oral form of Stafloxin with food can significantly affect how it is absorbed by the body. The presence of food can delay absorption, which can result in lower peak concentrations of the medicine in the bloodstream. For this reason, official guidance specifies taking it on an empty stomach.


Q: How long does Stafloxin stay in the body after the last dose?

The medicine is generally cleared from the bloodstream relatively quickly. Studies on the elimination process, known as the half-life, indicate the concentration of the drug significantly reduces within a few hours of the last dose in most healthy adults.


Q: Is Stafloxin a controlled substance?

Stafloxin is regulated as a Prescription-Only Medicine (POM) or similar category in many regions. It is not generally classified as a controlled substance that is subject to special restrictions related to potential for dependency or abuse.


Q: What does official guidance say about Stafloxin and alcohol consumption?

Regulatory guidance does not typically list alcohol consumption as strictly prohibited while taking Stafloxin. However, it is noted that alcohol may potentially increase the risk of experiencing some common gastrointestinal side effects, such as nausea or vomiting.


Q: Is Stafloxin known to affect sleep patterns or cause insomnia?

Insomnia is not widely listed as a common or specific adverse reaction for Stafloxin in regulatory documents. However, official information does classify certain nervous system effects, such as headaches and dizziness, which may indirectly affect sleep quality.


Q: Why is hydration sometimes emphasized when taking Stafloxin?

Patient guidance often emphasizes swallowing the oral forms, such as capsules, with a full glass of water. This specific guidance is often given to support the proper delivery into the stomach, which may help to reduce the risk of irritation or pain in the food pipe (esophagus).


Q: Are there specific food items or drinks that must be avoided while on Stafloxin?

Official guidance primarily focuses on the need to take the oral formulation on an empty stomach because the presence of any food can interfere with absorption. Specific food items other than general food consumption are not noted as being prohibited.


Q: Can Stafloxin be used for a viral infection?

Stafloxin is officially classified as an antibiotic, and its therapeutic indications are specifically limited to the treatment of infections caused by susceptible bacterial pathogens. It is not designed for, nor indicated for, use against viral infections.


Q: Can I drive or operate machinery while taking Stafloxin?

Official documents often state that Stafloxin is not known to impair the ability to drive or use machinery. However, official documents note that caution may be necessary if a patient experiences side effects such as dizziness or headaches, which are listed as possible adverse reactions.


Q: Are there genetic factors that might change how Stafloxin works for someone?

Official research and medical literature describe that specific genetic factors, particularly certain human leukocyte antigen (HLA) alleles, are recognized as established risk factors associated with drug-induced liver injury (DILI) related to Stafloxin.


Q: Is there a maximum length of time Stafloxin can be used for?

The length of use is determined by the prescribing medical professional. However, regulatory warnings note that an increased risk of severe liver events, such as cholestatic jaundice, is specifically associated with prolonged treatment or use for more than 14 days.


Q: Does Stafloxin have an effect on gut bacteria?

Regulatory documents list gastrointestinal side effects like diarrhea and, rarely, pseudomembranous colitis. These effects are officially linked to antibiotic-associated disruption of the normal bacterial flora in the gut.


Q: Why do official documents sometimes mention 'uncommon' or 'rare' side effects?

Regulatory documents use these terms as part of a standardized classification system to inform users about the likelihood of documented adverse reactions. For instance, 'Uncommon' indicates a frequency between 1 in 100 and 1 in 1,000 users, based on clinical data.


Q: Is the liquid form of Stafloxin absorbed differently than the tablet form?

The official requirement to take the medicine on an empty stomach for optimal absorption applies to both the capsule and liquid (suspension) oral forms. Some clinical studies, particularly in pediatric patients, note that absorption of the liquid form may not be as significantly affected by food as the capsule form.


Q: If I have a history of seizures, can I still use Stafloxin?

Official warnings focus on the risk of neurotoxicity, which includes the potential for convulsions or seizures, when high doses are used in patients with severe kidney impairment. This warning is relevant for the assessment of use in individuals who have a history of seizure disorders.


Q: Is it true that the effectiveness of Stafloxin is monitored by resistance levels?

The drug's effectiveness is officially linked to its ability to maintain drug concentrations above a level required to kill the target bacteria, known as the Minimum Inhibitory Concentration (MIC). Research confirms that low concentrations can lead to ineffective treatment and possible antimicrobial resistance.


Q: What should I do if I experience an unexpected side effect from Stafloxin?

Patient guidance describes that unexpected side effects or those that are severe or concerning are typically reported immediately to a healthcare professional, such as a doctor or pharmacist. Official drug agencies also provide mechanisms for patients to report suspected adverse reactions.


Q: Is it normal to feel tired or fatigued when taking Stafloxin?

While fatigue or tiredness is not typically listed in regulatory documents as a 'Common' side effect (1 in 100), some patient information materials describe these as potential, though less frequent, symptoms that should be mentioned to a healthcare professional if they occur.

How should Stafloxin be stored and disposed of?

Storage and Disposal Requirements

Storage and disposal of Stafloxin (Flucloxacillin) must adhere strictly to official regulatory guidelines to maintain product stability and ensure safety.

Storage Conditions

Product Form Temperature and Environment Stability Requirement
Dry Powder/Capsules Store at a temperature not exceeding 25 C and protect from light. Store in original packaging.
Reconstituted Suspension Store in a refrigerator (2 C to 8 C). Discard unused portion after 14 days.

All forms of the medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Stafloxin must not be disposed of via wastewater or household trash due to environmental concerns. The official method is to utilize a drug take-back program. If a take-back program is unavailable, mix the medicine with an undesirable substance (such as dirt) and place it in a sealed container before disposal in household trash, per official guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stafloxin found in:

A-Z Index: